NTSR1 and prostate cancer: New nanoparticles labeled with radioisotopes, such as 64Cu-labeled NT analogs, were tested in PC3 (androgen-resistant prostate cancer cell line) cell xenografts and showed promise for identifying NTR-positive lesions with low uptake in normal tissues, which could help predict patient responses to NTR1-targeted therapies [58].